Cediranib: Difference between revisions

Cediranib
Clinical data
Routes of; administration	Oral
ATC code	none;
Pharmacokinetic data
Elimination half-life	12 to 35 hours
Identifiers
	IUPAC name 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline;
CAS Number	288383-20-0 ;
PubChem CID	9933475;
ChemSpider	8109103 ;
UNII	NQU9IPY4K9;
CompTox Dashboard (EPA)	DTXSID10183035 ;
ECHA InfoCard	100.196.628
Chemical and physical data
Formula	C25H27FN4O3
Molar mass	450.505 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc4nc5ccc(Oc3ncnc2cc(OCCCN1CCCC1)c(OC)cc23)c(F)c5c4;
	InChI InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3 ; Key:XXJWYDDUDKYVKI-UHFFFAOYSA-N ;
	(what is this?) (verify)

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 15:04, 17 March 2014

Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.^[1]^[2]^[3]

It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.

Beginning in 2007, it underwent Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.

On February 27, 2008, AstraZeneca announced that the use of Cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.

On 8th March 2010, AstraZeneca issued a press-release stating that Cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader bevacizumab^[4] .

As of November 2012, it is currently in double-blind studies for the treatment of methylated Glioblastoma Multiforme at the University of Washington Medical Center at a 20mg daily dose.

References

^ Wedge SR, Kendrew J, Hennequin LF; et al. (May 2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
^ Goss G, Shepherd FA, Laurie S; et al. (December 2008). "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group". Eur. J. Cancer. 45 (5): 782–8. doi:10.1016/j.ejca.2008.10.022. PMID 19091548. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
^ Nikolinakos P, Heymach JV (June 2008). "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies". J Thorac Oncol. 3 (6 Suppl 2): S131–4. doi:10.1097/JTO.0b013e318174e910. PMID 18520296.
^ "AstraZeneca - RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer". Retrieved 17 March 2014.

External links

AZD2171—AstraZeneca Pipeline

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[pmid15899831-1] Wedge SR, Kendrew J, Hennequin LF; et al. (May 2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)

[pmid19091548-2] Goss G, Shepherd FA, Laurie S; et al. (December 2008). "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group". Eur. J. Cancer. 45 (5): 782–8. doi:10.1016/j.ejca.2008.10.022. PMID 19091548. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)

[pmid18520296-3] Nikolinakos P, Heymach JV (June 2008). "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies". J Thorac Oncol. 3 (6 Suppl 2): S131–4. doi:10.1097/JTO.0b013e318174e910. PMID 18520296.

[4] "AstraZeneca - RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer". Retrieved 17 March 2014.

[1]

[2]

[3]

[4]

@@ Line 54: / Line 54: @@
 It is being developed by [[AstraZeneca]] as a possible anti-cancer chemotherapeutic agent for oral administration.
-Beginning in 2007, it is undergoing [[Clinical trial#Phase I|Phase I]] [[clinical trial]]s for the treatment of [[Lung cancer#Non-small cell lung cancer|non-small cell]] [[lung cancer]], [[kidney cancer]], and [[colorectal cancer]] in adults, as well as tumors of the [[central nervous system]] in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.
+Beginning in 2007, it underwent [[Clinical trial#Phase I|Phase I]] [[clinical trial]]s for the treatment of [[Lung cancer#Non-small cell lung cancer|non-small cell]] [[lung cancer]], [[kidney cancer]], and [[colorectal cancer]] in adults, as well as tumors of the [[central nervous system]] in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.
-On February 27, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
+On February 27, 2008, AstraZeneca announced that the use of Cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
-On 8th March 2010, AstraZeneca issued a press-release stating that Recentin had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader [[bevacizumab]].
+On 8th March 2010, AstraZeneca issued a press-release stating that Cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader [[bevacizumab]]<ref>{{cite web|title=AstraZeneca - RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer|url=http://www.astrazeneca.com/Media/Press-releases/Article/20100308--RECENTIN-did-not-meet-primary-endpoint-in-Horizon-III|accessdate=17 March 2014}}</ref> .
 As of November 2012, it is currently in double-blind studies for the treatment of methylated Glioblastoma Multiforme at the University of Washington Medical Center at a 20mg daily dose.
 ==References==
 {{reflist}}
-http://www.astrazeneca.com/media/latest-press-releases/2010-new/recoentin-horizon?itemId=8748245
 ==External links==